LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
AgeUp to 22
SponsorM.D. Anderson Cancer Center
About this trial
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
Eligibility criteria
Qualifiers
Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
Patient may not receive chemotherapy concurrent with radiation
Signed informed consent by patient and/or parents or legal guardian
Disqualifiers
Patients with previous radiation therapy to the brain
Ependymoma of the spine
Disseminated ependymoma requiring craniospinal radiation therapy
Pregnancy
Trial design
Treatments tested in this trial
- Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Quality-of-Life Assessment
- Questionnaire Administration
Treatment groups
48 Participants
are divided into 1 treatment groupSponsors and collaborators
M.D. Anderson Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov